natgillin/translations-raw huggingface dataset:
A statistically significant decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was seen in all three studies in which it was assessed (RA studies I, III, IV). 
V vseh treh študijah (študije revmatoidnega artritisa I, III in IV), v katerih so ocenjevali utrujenost s funkcijsko oceno terapije kronične bolezni (Functional assessment of chronic illness therapy (FACIT)), so ugotovili statistično značilno zmanjšanje utrujenosti.
There is limited safety experience in patients undergoing arthroplasty while receiving adalimumab. 
Izkušnje z varnostjo pri bolnikih, ki so jim med zdravljenjem z adalimumabom opravili artroplastiko,
The recommended Imraldi induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160 mg at week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days) and 80 mg at week 2 (given as two 40 mg injections in one day). 
Priporočena shema odmerjanja zdravila Imraldi med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivnim ulceroznim kolitisom 160 mg 0. teden (aplicirano kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva dni zapored) in 80 mg 2. teden (aplicirano kot dve 40 mg injekciji v enem dnevu).
• paediatric uveitis. 
• uveitisa pri pediatrični populaciji.
Uncommon Lymphoma**, solid organ neoplasm (including breast cancer, lung neoplasm and thyroid neoplasm), melanoma** 
pogosti karcinom kože, ki ne vključuje malignega melanoma (vključno z bazalnoceličnim karcinomom in ploščatoceličnim karcinomom), benigni tumor občasni limfom**, tumorji parenhimskih organov (vključno s tumorjem dojk, tumorjem pljuč in tumorjem ščitnice), maligni melanom**
Following the administration of 24 mg/m2 (up to a maximum of 40 mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values measured at week 24) serum adalimumab concentrations were 8.8 ± 6.6 μg/ml for adalimumab without concomitant methotrexate and 11.8 ± 4.3 μg/ml with concomitant methotrexate. 
(do največ 40 mg) subkutano vsak drugi teden bolnikom z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednost merjena v 24. tednu) 8,8 ± 6,6 μg/ml med uporabo adalimumaba brez metotreksata in 11,8 ± 4,3 μg/ml med sočasno uporabo metotreksata.
Carefully pull off the clear needle cap with a metal center from the pen. 
Z injekcijskega peresnika previdno snemite prozorni pokrovček za iglo s kovinsko sredico.
Imraldi is contraindicated in moderate to severe heart failure (see section 4.3). 
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Imraldi kontraindicirano (glejte poglavje 4.3).
Talk to your doctor or pharmacist before using Imraldi. 
Pred začetkom uporabe zdravila Imraldi se posvetujte z zdravnikom ali farmacevtom.
Imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2). 
(acne inversa) pri mladostnikih, starejših od 12 let, ki se ne odzovejo zadovoljivo na konvencionalno sistemsko HS zdravljenje (glejte poglavji 5.1 in 5.2).
Adalimumab /methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 11). 
Pri bolnikih, ki so dobivali adalimumab in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 11) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Imraldi may have a minor influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Imraldi ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
Do not pass it on to others. 
NE PRIVIJTE je preveč.
Adults with rheumatoid arthritis 
Revmatoidni artritis pri odraslih
20 weeks 
≥ 90 dnia
Patients who experience insufficient response may benefit from an increase in dosage:  < 40 kg: 20 mg every week  ≥ 40 kg: 40 mg every week or 80 mg every other week 
• < 40 kg: 20 mg vsak teden • ≥ 40 kg: 40 mg vsak teden ali 80 mg vsak drugi teden
You will be instructed by your child's doctor or his/her assistant on the technique of injection and the amount to give to your child. Do not attempt to give your child an injection until you are sure that you understand how to prepare and give the injection. 
Otrokov zdravnik ali njegovo osebje vas bodo naučili, kako in koliko zdravila injicirate vašemu otroku.
 2 pre-filled pens, each with 1 alcohol pad  4 pre-filled pens, each with 1 alcohol pad  6 pre-filled pens, each with 1 alcohol pad 
Pakiranja po:  1 napolnjen injekcijski peresnik z 2 alkoholnima zložencema  2 napolnjena injekcijska peresnika, vsak z 1 alkoholnim zložencem  4 napolnjeni injekcijski peresniki, vsak z 1 alkoholnim zložencem  6 napolnjenih injekcijskih peresnikov, vsak z 1 alkoholnim zložencem
• fungal infections; 
• glivične okužbe;
Pull off the clear needle cap 
Snemite prozorni pokrovček za iglo
Imraldi in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. 
- Zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih bolnikih, kadar odziv na imunomodulirajoča antirevmatična zdravila, vključno z metotreksatom, ni zadosten.
Multiple sclerosis, demyelinating disorders (e.g. optic neuritis, Guillain-Barré syndrome)1) 
stisnjenje živčnih korenin občasni možgansko-žilni dogodki tremor, nevropatija redki multipla skleroza, demielinizirajoče bolezni (npr. optični nevritis, sindrom Guillain-Barré)
The recommended dose of Imraldi for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the initial dose. 
Priporočeno odmerjanje zdravila Imraldi za odrasle bolnike je začetni odmerek 80 mg subkutano in nato 40 mg subkutano vsak drugi teden, začenši en teden po začetnem odmerku.
• Keep your vial in its carton, and away from light. 
• Vialo shranite v njeni kartonski škatli in zaščiteno pred svetlobo.
Imraldi 40 mg solution for injection in vial is supplied as a 0.8 ml clear and colourless solution. 
Zdravilo Imraldi 40 mg raztopina za injiciranje v viali je na voljo v obliki 0,8 ml bistre in brezbarvne raztopine.
Imraldi 40 mg/0.8 ml injection adalimumab 
Imraldi 40 mg/0,8 ml raztopina za injiciranje adalimumab
• Throw away your used vial in a special container as instructed by your doctor, nurse or pharmacist. 
• Uporabljeno vialo zavrzite v poseben vsebnik, kot so vam naročili zdravnik, medicinska sestra ali farmacevt.
The recommended dose of Imraldi for adult patients with uveitis is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. 
Priporočeni začetni odmerek zdravila Imraldi za odrasle bolnike z uveitisom je 80 mg, čemur sledi 40 mg odmerek vsak drugi teden, ki se ga začne dajati en teden po začetnem odmerku.
This medicinal product contains 20 mg sorbitol in each pre-filled syringe. 
To zdravilo vsebuje 20 mg sorbitola v napolnjeni injekcijski brizgi.
Imraldi 40 mg solution for injection in pre-filled syringe is supplied as a 0.8 ml clear and colourless solution. 
Zdravilo Imraldi 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku je na voljo v obliki 0,8 ml bistre in brezbarvne raztopine.
Syringe disposal 
Odstranjevanje injekcijske brizge
Treatment with Imraldi must be discontinued in patients who develop new or worsening symptoms of congestive heart failure. 
Pri bolnikih, ki se jim na novo pojavijo simptomi kongestivnega srčnega popuščanja ali se jim takšni simptomi poslabšajo, je treba zdravljenje z zdravilom Imraldi prekiniti.
Your child's doctor may also prescribe an initial dose of 80 mg which may be administered one week prior to the start of the usual dose. 
Zdravnik lahko vašemu otroku predpiše začetni odmerek 80 mg, ki se ga uporabi en teden pred začetkom zdravljenja z običajnim odmerkom.
Pull off needle cap 
Snemite pokrovček za iglo
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (PRE-FILLED SYRINGE PACK) 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA (PAKIRANJE Z NAPOLNJENIM INJEKCIJSKIM PERESNIKOM)
If a faster effect is required your doctor may prescribe an initial dose of 160 mg (as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg (as two 40 mg injections in one day) two weeks later, and thereafter as 40 mg every other week. 
Če je potreben hitrejši učinek, vam zdravnik lahko predpiše začetni odmerek 160 mg (kot štiri 40 mg injekcije na en dan ali kot dve 40 mg injekciji na dan dva dni zapored), ki mu sledi 80 mg (kot dve 40 mg injekciji v enem dnevu) dva tedna kasneje in potem 40 mg vsak drugi teden.
• Throw away your used syringe in a special container as instructed by your doctor, nurse or pharmacist. 
• Uporabljeni injekcijski peresnik zavrzite v poseben vsebnik, kot so vam naročili zdravnik, medicinska sestra ali farmacevt.
The usual dose for adults with non-infectious uveitis is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg given every other week starting one week after the initial dose. 
Običajni začetni odmerek za odrasle z neinfekcijskim uveitisom je 80 mg (kot dve 40 mg injekciji v enem dnevu), čemur sledi odmerek 40 mg, ki se ga daje vsak drugi teden, z začetkom en teden po začetnem odmerku.
RA study IIIa** 
Študija revmatoidnega artritisa IIIa**
Imraldi 40 mg solution for injection in pre-filled syringe adalimumab 
Imraldi 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab
The usual Imraldi dose for adults with ulcerative colitis is 160 mg initially (as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days) followed by 80 mg (as two 40 mg injections in one day) two weeks later and thereafter 40 mg every other week. 
Običajno odmerjanje zdravila Imraldi pri odraslih z ulceroznim kolitisom je 160 mg (kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva zaporedna dneva) 0. teden in 80 mg (kot dve 40 mg injekciji v enem dnevu) 2. teden, nato pa 40 mg vsak drugi teden.
and uveitis patients. 
3.000 bolnikih.
The recommended dose of Imraldi is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg every other week starting one week later. 
Priporočeno odmerjanje zdravila Imraldi je začetni odmerek 80 mg (dve 40 mg injekciji v enem dnevu), čemur sledi 40 mg vsak drugi teden z začetkom en teden po začetnem odmerku.
Table 6 Undesirable Effects 
Neželeni učinki
Adalimumab/methotrexate combination therapy was clinically and statistically superior to methotrexate (p <0.001) and adalimumab monotherapy (p <0.001) in achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. 
Za doseganje nizkega stanja bolezni pri bolnikih z nedavno diagnosticiranim zmernim do hudim revmatoidnim artritisom je bila kombinirana terapija z adalimumabom in metotreksatom klinično in statistično boljša od monoterapije z metotreksatom (p < 0,001) in monoterapije z adalimumabom (p < 0,001).
• kidney problems; 
• težave z ledvicami;
ACR 50 52 Week 
52. tedna dosegli odziv ACR 50.
There is no relevant use of adalimumab in children aged below 6 years for this indication. 
Uporaba adalimumaba pri otrocih, starih manj kot 6 let, za to indikacijo ni primerna.
Citric acid monohydrate Histidine 
Pomožne snovi: natrijev citrat, citronska kislina monohidrat, histidin, histidinijev klorid monohidrat,
Adalimumab Δ Censored Note: P = Placebo (Number at Risk (flared)); A = Adalimumab (Number at Risk (flared)). 
Opomba: P = placebo (število rizičnih preiskovancev (zagon bolezni)); A = adalimumab (število rizičnih preiskovancev (zagon bolezni)).
The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a Physician's Global Assessment (PGA) ≥4 or >20% BSA involvement or >10 % BSA involvement with very thick lesions or Psoriasis Area and Severity Index (PASI) ≥20 or ≥10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy. 
Učinkovitost adalimumaba je bila ocenjena v randomizirani, dvojno slepi, kontrolirani študiji, v katero je bilo vključenih 114 pediatričnih bolnikov od 4. leta starosti, s hudo kronično psoriazo v plakih (definirano z zdravnikovo globalno oceno (PGA - Physician's Global Assessment) ≥ 4 ali > 20 %
If a faster response is required, your child's doctor may prescribe an initial dose of 80 mg (as two 40-mg injections in 1 day) followed by 40 mg two weeks later. 
Če je potreben hitrejši odziv, lahko zdravnik vašemu otroku predpiše začetni odmerek 80 mg (kot dve 40 mg injekciji v enem dnevu), ki mu sledi 40 mg dva tedna kasneje.
Uncommon Rhabdomyolysis, systemic lupus erythematosus 
sistemski eritematozni lupus redki sindrom, podoben lupusu
Very common Lipids increased Common 
Presnovne in prehranske motnje zelo pogosti zvišanje lipidov pogosti hipokaliemija,
In patients with ulcerative colitis, a loading dose of 160 mg adalimumab on week 0 followed by 80 mg adalimumab on week 2 achieves serum adalimumab trough concentrations of approximately 12 μg/ml during the induction period. 
Pri bolnikih z ulceroznim kolitisom doseže polnilni odmerek 160 mg adalimumaba na 0. teden, ki mu sledi 40 mg adalimumaba 2. teden, med obdobjem indukcije najmanjšo koncentracijo v serumu približno 12 µg/ml.
Imraldi 40 mg solution for injection in pre-filled syringe EU/1/17/1216/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM EU/1/17/1216/009
Imraldi is also used to treat severe plaque psoriasis in children and adolescents weighing 30 kg or greater for whom topical therapy and phototherapies have either not worked very well or are not suitable. 
ki tehtajo 30 kg ali več, pri katerih lokalno zdravljenje in fototerapija nista dovolj dobro delovala ali pa nista primerna.
• When the syringe is empty, remove the needle from skin, being careful to pull it out at the same angle as when it was inserted. 
• Ko je brizga prazna, iglo potegnite iz kože.
If a faster response is required, your doctor may prescribe an initial dose of 80 mg (as two 40 mg injections in one day) followed by 40 mg two weeks later. 
Če je potreben hitrejši odziv, vam zdravnik lahko predpiše začetni odmerek 80 mg (kot dve 40 mg injekciji v enem dnevu), ki mu sledi 40 mg dva tedna kasneje.
The usual dose regimen for hidradenitis suppurativa is an initial dose of 160 mg (as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by an 80 mg dose (as two 40 mg injections in one day) two weeks later. 
Običajni začetni odmerek je 160 mg (kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva zaporedna dneva), ki mu sledi odmerek 80 mg (kot dve 40 mg injekciji v enem dnevu) dva tedna kasneje.
Of 207 patients, 81 patients continued on adalimumab 40 mg every other week for 10 years. 
81 nadaljevalo zdravljenje s 40 mg adalimumaba vsak drugi teden še 10 let.
Stratum 
RTa
* p <0.001 for adalimumab versus placebo pairwise comparisons of proportions ** p <0.02 for adalimumab versus placebo pairwise comparisons of proportions a Of those receiving corticosteroids at baseline 
Bolniki v remisiji brez steroidov ≥ 90 dnia * p < 0,001 za parne primerjave deležev med adalimumabom in placebom ** p < 0,02 za parne primerjave deležev med adalimumabom in placebom a Od tistih, ki so izhodiščno dobivali kortikosteroide
Check with your doctor before your child receives any vaccines. 
Preden vaš otrok opravi kakršnokoli cepljenje, se posvetujte z zdravnikom.
It is important to tell your doctor if your child gets symptoms such as fever, wounds, feeling tired or dental problems. 
Pomembno je, da zdravniku poveste, če vaš otrok doživi simptome, kot so npr. zvišana telesna temperatura, rane, občutek utrujenosti ali težave z zobmi.
**p <0.01, adalimumab versus placebo - Not applicable 
c MTX = metotreksat **p < 0,01, adalimumab v primerjavi s placebom - Ne pride v poštev
Skin Painb 
ali stegna.
• adolescent hidradenitis suppurativa, 
• hidradenitis suppurativa pri mladostnikih,
It is important that you tell your doctor if your child has symptoms of infections, e.g. fever, wounds, feeling tired, dental problems. 
Pomembno je, da zdravniku poveste, če ima vaš otrok simptome okužb, npr. zvišano telesno temperaturo, rane, občutek utrujenosti ali težave z zobmi.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (VIAL PACK) 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA (PAKIRANJE Z VIALO)
CD study I: Infliximab Naive Patients 
Študija pri Crohnovi bolezni I: Bolniki, ki še niso dobivali infliksimaba
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE (UČINKOVIN) IN
and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg adalimumab every other week or placebo for an additional 19 weeks. 
Bolnike, ki so imeli 33. teden ohranjen odziv PASI ≥ 75 in so bili v obdobju A randomizirani na aktivno terapijo, so med obdobjem C ponovno randomizirali tako, da so dodatnih 19 tednov dobivali 40 mg adalimumaba vsak drugi teden ali placebo.
Keep the syringe in the outer carton in order to protect from light. 
Brizgo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Imraldi is used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years in whom topical therapy and phototherapies have either not worked very well or are not suitable. 
4 leta do 17 let, pri katerih lokalno zdravljenje in fototerapija nista dovolj dobro delovala ali pa nista primerna.
Week 16 Placebo-Controlled 
Kontrolirana s placebom
If these medicines do not work well enough, patients will be given Imraldi to reduce the signs and symptoms of your disease. 
Če ta zdravila ne bodo delovala dovolj dobro, bodo bolniki za zmanjšanje znakov in simptomov bolezni dobili zdravilo Imraldi.
In monotherapy, some patients who experience a decrease in their response to Imraldi 40 mg every other week dosing may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other week. 
Med monoterapijo lahko nekaterim bolnikom, ki se jim odziv na zdravilo zmanjša, koristi zvečanje odmerka adalimumaba na 40 mg vsak teden.
Talk to your child's doctor or pharmacist before using Imraldi. 
Pred začetkom uporabe zdravila Imraldi se posvetujte z zdravnikom vašega otroka ali farmacevtom.
Inhibition of inflammation 
Shranjevanje injekcijske brizge
Autoantibodies Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies 
V študijah revmatoidnega artritisa I−V so pri bolnikih ob več različnih časih testirali protitelesa v serumu.
solution for injection 1 pre-filled syringe 2 alcohol pads 
raztopina za injiciranje 1 napolnjena injekcijska brizga
Your child's doctor should test your child for HBV. Imraldi can reactivate HBV infection in people who carry this virus. 
Zdravnik mora vašega otroka testirati na HBV.
The usual dose for adults with psoriasis is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg given every other week starting one week after the initial dose. 
Običajni začetni odmerek za odrasle z luskavico (psoriazo) je 80 mg (kot dve 40 mg injekciji v enem dnevu), nato pa 40 mg vsak drugi teden z začetkom en teden po začetnem odmerku.
• ear infections; 
• okužbe ušesa;
If this dose does not work well enough, your child's doctor may increase the dosage to 40 mg every week or 80 mg every other week. 
Če ta odmerek ne deluje dovolj dobro, lahko zdravnik vašega otroka odmerek poveča na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Children and adolescents from 4 to 17 years of age weighing 15 kg to less than 30 kg The recommended dose of Imraldi is an initial dose of 20 mg, followed by 20 mg one week later. 
Otroci in mladostniki, starejši od 6 let, ki tehtajo od 15 kg do manj kot 30 kg Priporočeni odmerek zdravila Imraldi je 20 mg vsak drugi teden.
There is no relevant use of adalimumab in children aged less than 2 years in this indication. 
Uporaba adalimumaba pri otrocih, mlajših od 2 let, za to indikacijo ni primerna.
DO NOT touch the vial stopper after wiping with the alcohol pad. 
Potem, ko ste zamašek viale obrisali z alkoholnim zložencem, se zamaška NE DOTIKAJTE.
Adalimumab was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. 
V vseh kliničnih preskušanjih revmatoidnega artritisa so adalimumab ocenili pri več kot
RA study Ia** 
Študija revmatoidnega artritisa Ia**
Rare 
adalimumabb
If a faster response is required, your child's doctor may prescribe an initial dose of 160 mg initially (as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg (as two 40 mg injections in one day) two weeks later. 
Če je potreben hitrejši odziv, lahko zdravnik vašemu otroku predpiše začetni odmerek 160 mg (kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva zaporedna dneva), ki mu sledi 80 mg (kot dve 40 mg injekciji v enem dnevu) dva tedna kasneje.
This medicinal product contains 20 mg sorbitol in each pre-filled pen. 
To zdravilo vsebuje 20 mg sorbitola v napolnjenem injekcijskem peresniku.
7.2 % of patients receiving placebo or active control. 
1,3 % bolnikov v kontrolni skupini.
Biogen Inc. 
Icepharma hf.
The primary endpoint in RA study V was the percent of patients who achieved an ACR 50 response at week 52. 
Primarna končna točka študije revmatoidnega artritisa V je bil odstotek bolnikov, ki so do
If this dose does not work well enough to Imraldi 40 mg every other week, your doctor may increase the dosage to 40 mg every week or 80 mg every other week . 
Če odziv na zdravilo Imraldi 40 mg vsak drugi teden ne bo zadosten, bo zdravnik odmerek lahko povečal na 40 mg vsak teden ali na 80 mg vsak drugi teden.
μg/ml (95% CI: 1-6 μg/ml). 
ICAM-1 z IK50 0,1-0,2 nM).
• 40 mg at week 0 and 20 mg at week 2 
40 mg 2. teden oziroma 40 mg 0. teden in 20 mg 2. teden.
EU/1/17/1216/008 
EU/1/17/1216/007 EU/1/17/1216/008
Imraldi 40 mg solution for injection in pre-filled syringe 
Imraldi 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
• If you dropped your syringe with the cap ON, it is okay to use the syringe. 
• Če vam je injekcijska brizga padla, ko je bil pokrovček še NAMEŠČEN, jo smete uporabiti.
Children, adolescents and adults with enthesitis-related arthritis Children and adolescents from 6 years of age weighing 15 kg to less than 30 kg The recommended dose of Imraldi is 20 mg every other week. 
Otroci, mladostniki in odrasli s poliartikularnim juvenilnim idiopatskim artritisom Otroci in mladostniki, starejši od 2 let, ki tehtajo od 10 kg do manj kot 30 kg Priporočeni odmerek zdravila Imraldi je 20 mg vsak drugi teden.
• psoriasis, 
oniholiza,
14 weeks a Ped ACR 30/50/70 responses week 48 significantly greater than those of placebo treated patients b p = 0.015 c p = 0.031 
> 32 tednov 20 tednov > 32 tednov 14 tednov a Odzivi »Paed ACR« 30/50/70 so bili 48. teden značilno večji kot pri bolnikih, ki so dobivali placebo.
Confirm completion & dispose 
Prepričajte se, da je injiciranje zaključeno, in zavrzite
Each 0.8 ml pre-filled syringe contains 40 mg adalimumab. 
Ena 0,8 ml napolnjena injekcijska brizga z enim odmerkom vsebuje 40 mg adalimumaba.
• Keep your syringe in its carton, and away from light. 
• Injekcijsko brizgo shranite v njeni kartonski škatli in zaščiteno pred svetlobo.